Based on the relationship between government and market,this paper analyzed the development process of large medical equipment configuration management strategy,and forecasted the trend of management.It is found that the development process of large equipment management in China can be divided into four stages:sprouting stage,management window period,growth stage,and transition period.The management model of the four stages,respectively,are integrated management,market-oriented management,quantitative control-based comprehensive supervision,and legal supervision.As per the analysis of this work,it was found that the sprouting of the regulation of industry standards,training professionals,management efficiency are low;market-oriented led to rapid growth in the number of equipment,with a low configuration efficiency;growth period of the number of regulatory norms of the market and equipment is reasonable to use;and the legal supervision in transition is taking shape.Currently,the lack of rational allocation of large-scale equipment in the hospitals is the main factor leading to market failure.In the legal framework,the government intervention with configuration permits is the major large-scale equipment configuration management model in the future.

Ductal carcinoma in situ(DCIS),a pathological type of breast cancer that is limited to the terminal ducts of the breast without breaking through the basement membrane,is considered as the precursor of invasive ductal carcinoma(IDC).When DCIS breaks through the basement membrane and invades surrounding tissues,it can form infiltrating lesions.If the maximum diameter of a single infiltrating lesion is less than 1mm or the maximum diameter of multiple infiltrating lesions is less than 1mm,it is defined as ductal carcinoma in situ with microinvasion(DCIS-Mi).About 12%-40%of untreated and intervened DCIS will progress to IDC,and DCIS and IDC can also coexist.However,there is a considerable portion of DCIS that never progresses with good prognosis.Recently,overdiagnosis and overtreatment of DCIS have become the research hotspots.The histological grade of DCIS is mainly based on the morphology of the nucleus,which is divided into three nuclear levels:low,medium,and high.There are also significant differences in receptor expression and molecular type distribution between DCIS,DCIS-Mi,and IDC.For DCIS with or without microinvasion as well as different histological grades,there are many controversies about the treatment regimen,clinical prognosis and risk.The development of modern imaging technology has achieved preliminary evaluation of histological grading,infiltration status,and prognosis prediction of DCIS.The most commonly used breast imaging techniques in clinical practice currently include mammography(MG),ultrasound(US),and magnetic resonance imaging(MRI).The imaging principles of these three techniques are different,and each has its own advantages and disadvantages in breast disease imaging diagnosis.However,they can complement each other and play an important role in disease diagnosis,treatment,and prognosis evaluation.Mammography has the advantages of safety,reliability and good repeatability.It is the preferred screening method for breast cancer recommended by international guidelines.The main manifestations of DCIS on MG can be divided into non calcified lesions and calcified lesions.On US,the main manifestations are lesions and non-lesion type,which can be further divided into hypoechoic changes,calcification,ductal changes,and structural disorders and distortions.MRI has higher sensitivity in detecting DCIS without calcification and multifocal DCIS compared with MG,and has higher accuracy in evaluating the lesion range.However,there are also shortcomings such as low diagnostic specificity and insensitivity to microcalcification display.In addition,radiomics has great potential in the histopathological evaluation,prediction,and guidance of individualized precision treatment of DCIS.In the current era of precision medicine,image features,histopathology,molecular genes,etc.are increasingly significant in predicting the prognosis of breast cancer.The early accurate diagnosis and molecular type of DCIS are also extremely important in clinical work.It has become a consensus in clinical treatment to predict the potential benefits of different treatments through molecular typing,histological grade,and imaging findings,in order to develop the most suitable personalized treatment plan.This article reviewed the correlation between imaging features and the molecular subtype,histopathology and prognosis of DCIS.

At present,the development of enhanced recovery after surgery(ERAS)pathways in deep inferior epigastric perforator(DIEP)flap breast reconstruction is still in the initial stage worldwide,lacking established guidelines.In the multidisciplinary ERAS pathways,the department of anesthesiology is responsible for some core elements such as optimizing anestheticprotocols,perioperative fluid management and homeostasis regulation,prevention of hypothermia,improvement of perioperative analgesia,and postoperative nausea and vomiting prophylaxis.We summarized the anesthetic management in the ERAS pathways for patients undergoing DIEP flap breast reconstruction in Fudan University Shanghai Cancer Center,along with the recent progress,aiming to establish and improve the perioperative strategy based on ERAS pathways in DIEP flap breast reconstruction.

Objective:To investigate the effect of occupational stress on mental health of anesthesia nurses in Shanghai tertiary and first-class hospitals. These results provide theoretical basis for managers to adjust the allocation of human resources, reduce the professional pressure of anesthesia nurses and promote the development of anesthesia nursing.Methods:A questionnaire survey was conducted among 229 anesthetic nurses in 11 tertiary and first-class hospitals in Shanghai using Chinese Nurses Work Stressors Scale and Symptom Checklist 90 (SCL-90). Each dimension and item of the stress source scale and symptom Checklist-90 for anesthesia nurses were scored, and the effects of occupational stress on mental health were analyzed.Results:The mental health status of anesthesia nurses was positively correlated with occupational stress. The occupational stressors with the highest correlation coefficient with mental health factors was"management and interpersonal relationship"dimension( P<0.01). The five dimensions of occupational stress were the highest correlation coefficient of "obsessive compulsive symptoms" in mental health factors( P<0.01).In terms of nursing specialty and work: correlation coefficient r = 0.566; workload and time distribution: correlation coefficient was 0.477; work environment and resources: correlation coefficient was 0.477; patient care: correlation coefficient was 0.588; management and interpersonal relationship: correlation coefficient was 0.604.The results of multiple regression analysis showed that the independent variable"the management and interpersonal relationship" dimension of occupational stressors had influence on the dependent variable ten factors of mental health( P<0.01). And "independent variable nursing profession and work" had an impact on dependent variable "obsessive-compulsive symptoms" and "sleep-eating" factors( P<0.05); independent "variable workload and time allocation" had an impact on dependent variable "phobic" factors( P<0.05). Conclusions:The occupational stress of anesthetic nurses in Shanghai has an impact on mental health. "Management and interpersonal relationship" has the greatest impact on mental health in occupational stressors.

The incidence of prostate cancer in China is growing rapidly in recent years. The leapfrog development of prostate cancer research in China during the last 40 years has been witnessed by "Chinese Journal of Urology" and divided into three major periods. First, the beginning phase during 1980 to 2000, when the Chinese urology community began to establish a professional and standardized prostate cancer treatment system. Second, the catching-up phase during 2001 to 2010, when Chinese urologists actively promoted prostate cancer diagnosis and treatment technology, and integrated with international advanced diagnosis and treatment concept. Third, the characteristics creating phase during 2011 to 2020, when prostate cancer research in China developed rapidly, and the voice of China is constantly being heard on the international stage. Based on the current prostate cancer research in China, it is also necessary to strengthen evidence-based medicine research, to focus on precision medicine research, to pay attention to real-world research, and to emphasize the importance of differences between China and the western countries. At last, Chinese prostate cancer patients will benefit more.

With the renewal of minimally invasive concept and the progress in laparoscopic equipment, instruments and technology, reduced-port and single-port laparoscopic surgery had been applicated in the clinical practice. Compared with traditional laparoscopic gastrectomy, single-port laparosco-pic gastrectomy (SILG) has less trauma, better cosmetic effect, lighter postoperative pain and faster recovery, which has been considered to be the best way to improve the quality of life of patients in the early postoperative period. However, the technical difficulties of SILG for gastric cancer have limited its clinical application. Since the first report describing single-port laparoscopic distal gastrectomy in 2011, the safety of SILG has been preliminarily confirmed. However, prospective randomized trials comparing SILG with traditional laparoscopic gastrectomy are still required. Therefore, the extensive application of SILG is still controversial. Combined with relevant literatures and clinical experience, the authors investigate the current status and exis-ting problems of SILG.

Prostate cancer is the most common solid malignant tumor among men in Western countries. While the incidence of prostate cancer is relatively low in Asia. In recent years, the incidence of prostate cancer in Asia is growing rapidly due to the development of social and economic level, popularization of people's health awareness and technological progress of health medicine in Asian countries. However, the uneven level of economic, social, human and medical aspects in Asian countries has also brought some difficulties and challenges to the standardized diagnosis and treatment of prostate cancer. Based on the Asian population, combined with the characteristics of Asian countries, this paper will explore the future directions of prostate cancer diagnosis and treatment in Asia from the development of prostate cancer diagnosis and treatment in China.

In China, gastric cancer is the top three malignant tumors with high incidence and mortality, which seriously endangers the lives and health of people. The comprehensive treat-ment based on surgery is still the main treatment for gastric cancer. Through the unremitting efforts and hard works of gastric cancer experts, the treatment effect of gastric cancer in China has made great progress. However, gastric cancer surgery still faces some outstanding problems. How to further improve preoperative accurate diagnosis? How to further rationalize the treatment of early gastric cancer? Where is the future development of minimally invasive techniques for gastric cancer surgery? How to break through the bottleneck of conversion therapy? These are the challenges for gastric cancer surgery. Based on relevant literature and combined with own clinical practice, the author explores the hot issues of gastric cancer surgery.

Objective:To investigate the influence of neoadjuvant chemotherapy on safety and prognosis of patients undergoing multivisceral resection for gastric cancer.Methods:The pro-pensity score matching (PSM) and retrospective cohort study was conducted. The clinicopathological data of 144 patients with gastric cancer who underwent multivisceral resection in the Fudan University Shanghai Cancer Center from December 2011 to December 2020 were collected. There were 95 males and 49 females, aged (56±13)years. Of 144 patients, 27 cases undergoing neoadjuvant chemotherapy and postoperative adjuvant chemotherapy were divided into the neoadjuvant chemotherapy group, and 117 cases undergoing postoperative adjuvant chemotherapy were divided into the adjuvant chemotherapy group. Observation indicators: (1) PSM and comparison of general data of patients between the two groups after matching; (2) surgical and postoperative conditions; (3) prognosis. PSM was done by the 1∶1 nearest neighbor matching method, with the caliper setting as 0.02. Measurement data with normal distribution were expressed as Mean± SD. Measurement data with skewed distribution were expressed as M(range), and comparison between groups was conducted using the rank sum test. Count data were expressed as absolute numbers, comparison between groups was conducted using the chi-square test. Comparison of ordinal data was conducted using the non-parameter test. The Kaplan-Meier method was used to draw survival curves and calculate survival rate, and the Log-Rank test was used for survival analysis. Results:(1) PSM and comparison of general data of patients between the two groups after matching. Of 144 patients, 46 cases were successfully matched, including 23 cases in the neoadjuvant chemotherapy group and 23 cases in the adjuvant chemotherapy group, respectively. The elimination of preoperative hemoglobin, clinical TNM staging confounding bias ensured comparability between the two groups after PSM. (2) Surgical and postoperative conditions. Of 46 patients, 26 cases underwent gastrectomy with one organ resection, 16 cases underwent gastrectomy with two organs resection, and 4 cases underwent gastrectomy with three organs resection. Of the patients with multivisceral resection, the proportion of patients undergoing combined splenectomy, pancreatectomy, colon resection, liver resection, and small intes-tinal resection was 69.6%(32/46), 39.1%(18/46), 32.6%(15/46), 8.7%(4/46), 2.2%(1/46), respectively. Cases with D 1 lymph node dissection, cases with D 2 lymph node dissection, cases with R 0 resection, cases with R 1 resection in the neoadjuvant chemotherapy group and the adjuvant chemotherapy group were 1, 22, 23, 0 and 0, 23, 23, 0, respectively, showing no significant difference in the above indicators between the two groups ( P>0.05). The number of lymph node dissected, the volume of intraoperative blood loss, duration of postoperative hospital stay in the neoadjuvant chemotherapy group and the adjuvant chemotherapy group were 28(range, 22-37), 150 (range, 100-200)mL, 11(range, 8-16)days and 25(range, 18-32), 150(range, 100-200)mL, 11(range, 9-18)days, respec-tively, showing no significant difference in the above indicators between the two groups ( Z=-1.13, -0.32, -0.50, P>0.05). Cases with complications ≥grade Ⅱ of Clavien-Dindo classification during the postoperative 30 days were 2 in the neoadjuvant chemotherapy group, including 1 case of abdominal abscess and 1 case of pneumonia. Cases with complications ≥grade Ⅱ of Clavien-Dindo classification during the postoperative 30 days were 8 in the adjuvant chemotherapy group, including 3 cases of abdominal abscess, 2 cases of anastomotic fistula, 1 case of pneumonia, 1 case of pancreatic fistula, 1 case of gastric emptying disability. There were significant differences in the complications ≥grade Ⅱ of Clavien-Dindo classification between the neoadjuvant chemotherapy group and the adjuvant chemotherapy group ( χ2=4.60, P<0.05). There was no significant difference in the abdominal abscess, anastomotic fistula, pneumonia, pancreatic fistula, gastric emptying disability between the two groups ( P>0.05). None of patient died in either of the neoadjuvant chemotherapy group and the adjuvant chemotherapy group. (3) Prognosis. Of 46 patients, 43 cases were followed up for 15.4(range, 3.0-84.0)months. The overall survival time of patients in the neoadjuvant chemotherapy group and the adjuvant chemotherapy group were (14±10)months and (24±22)months, showing no significant difference between them ( hazard ratio=0.82, 95% confidence interval as 0.28-2.40, P>0.05). Conclusion:Compared with postoperative adjuvant chemotherapy, neoadjuvant chemotherapy does not increase the surgical risk of locally advanced gastric cancer patients undergoing multivisceral and radical resection, and can reduce the incidence of complications ≥grade Ⅱ of Clavien-Dindo classification during the postoperative 30 days, but does not improve patient survival.

Breast cancer is the most prevalent malignant tumor among women globally,posing a serious threat to women's health.With the establishment of staging and typing principles for breast cancer diagnosis and treatment,and the development and application of novel antitumor drugs,the survival and quality of life of breast cancer patients have been continuously improving.In China,the large base of breast cancer patients possesses unique incidence characteristics,necessitating ongoing exploration of more appropriate treatment strategies;the volume and level of clinical research are also continuously advancing.In 2023,significant clinical research results were reported for different subtypes of breast cancer.In surgical treatment,clinical trials on targeted axillary lymph node dissection and the establishment of a predictive model BRCA-CRisk for contralateral breast cancer risk provide more evidence for de-escalation in surgical treatment.In the area of human epidermal growth factor receptor 2(HER2)-positive breast cancer,pyrotinib has shown significant efficacy in advanced breast cancer treatment.In triple-negative breast cancer,precision subtype treatment and immunotherapy continue to improve patient survival.For hormone receptor-positive breast cancer,significant research results were obtained in exempting low-risk patients from chemotherapy and exploring alternative options after resistance to endocrine therapy.In the aspect of BRCA mutations,BGB-290-201 further confirmed the therapeutic efficacy and safety of poly(ADP-ribose)polymerase(PARP)inhibitors for the Chinese population.For advanced HER2-negative patients carrying germline BRCA(gBRCA)1/2 mutations,pamiparib will be an ideal treatment choice.This article reviews the important clinical research in the field of breast cancer in China in 2023,summarizes key results,and aims to provide reference ideas for future clinical research.